

Kishimoto Mitsumasa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4314341/publications.pdf>

Version: 2024-02-01

29
papers

1,061
citations

687220

13
h-index

501076

28
g-index

29
all docs

29
docs citations

29
times ranked

945
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 2108-2117.	6.3	223
2	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.5	188
3	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	13.9	143
4	Reactive arthritis after COVID-19 infection. <i>RMD Open</i> , 2020, 6, e001350.	1.8	117
5	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	1.8	64
6	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. <i>RMD Open</i> , 2021, 7, e001838.	1.8	42
7	Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. <i>Arthritis and Rheumatology</i> , 2022, 74, 70-80.	2.9	38
8	Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication. <i>Modern Rheumatology</i> , 2023, 33, 21-35.	0.9	35
9	Postoperative complications in patients with rheumatoid arthritis using a biological agent – A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2015, 25, 672-678.	0.9	33
10	Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1014-1021.	0.5	31
11	Clinical features of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101670.	1.4	22
12	Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 766-774.	1.6	15
13	Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. <i>Journal of Rheumatology</i> , 2019, 46, 896-903.	1.0	14
14	Patient Preference for Treatment Mode of Biologics in Rheumatoid Arthritis: A 2020 Web-based Survey in Japan. <i>Rheumatology and Therapy</i> , 2021, 8, 1095-1111.	1.1	12
15	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 74-86.	0.9	11
16	Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. <i>RMD Open</i> , 2021, 7, e001752.	1.8	11
17	The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis. <i>Japan College of Rheumatology 2014: Utilization of GRADE approach. Modern Rheumatology</i> , 2016, 26, 175-179.	0.9	10
18	LB0001 – EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PsA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 16.2-17.	0.5	10

#	ARTICLE	IF	CITATIONS
19	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 313-322.	0.9	7
20	Integrating patients'™ perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan. <i>Modern Rheumatology</i> , 2017, 27, 924-929.	0.9	6
21	Patients'™ perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. <i>Modern Rheumatology</i> , 2022, 32, 307-312.	0.9	6
22	Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 296-306.	0.9	5
23	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	1.8	5
24	Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis. <i>Rheumatology International</i> , 2022, 42, 1751-1766.	1.5	5
25	Pustular Psoriasis and Associated Musculoskeletal Disorders. <i>Journal of Rheumatology</i> , 2021, , jrheum.201673.	1.0	3
26	Response to: "Correspondence on "Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial"™™ by Zhao and Huang. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e169-e169.	0.5	2
27	Axial Spondyloarthritis in Japan. <i>Current Rheumatology Reports</i> , 2022, , 1.	2.1	2
28	Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 1825-1831.	1.5	1
29	Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. <i>Modern Rheumatology</i> , 2022, 32, 121-126.	0.9	0